News

Johnson & Johnson’s Multiple Myeloma Therapy Combination Receives Positive CHMP Opinion

Johnson & Johnson said the CHMP opinion is an important step towards positioning the off-the-shelf immunotherapy combination of teclistamab and daratumumab as a potential new standard of care earlier in the multiple myeloma treatment pathway.